Francesco Natalucci , Sandra Bisseron , Tatiana Sokolova , Aleksandra Avramovska , Dominique Maiter , Patrick Durez
{"title":"甲氨蝶呤会影响男性患者的性功能障碍吗?对 IIEF5 问卷和荷尔蒙状态的分析。","authors":"Francesco Natalucci , Sandra Bisseron , Tatiana Sokolova , Aleksandra Avramovska , Dominique Maiter , Patrick Durez","doi":"10.1016/j.jbspin.2024.105716","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The aim of this study is to evaluate the impact of methotrexate (MTX) on erectile function in male patients through the International Index of Erectile Function (IIEF5) questionnaire and hormonal dosage.</p></div><div><h3>Methods</h3><p>Male patients affected by inflammatory arthritis (rheumatoid arthritis [RA] or psoriatic arthritis [PsA]) with good disease control and treated with chronic MTX were enrolled. Age-matched patients affected by chronic arthritis not treated with MTX were enrolled as controls. Each patient had a complete sexual hormone evaluation. IIEF5 questionnaire was administered to each patient.</p></div><div><h3>Results</h3><p>One hundred and nine patients were included, 77 in the MTX group and 32 as controls. The median weekly MTX dose was 10<!--> <!-->mg (IQR 7.5) with a median MTX duration therapy of 8 years (IQR 17). The total IIEF5 score was lower in patients MTX exposed compared to the control group without a significant result. The total IIEF5 score of patients treated with MTX<!--> <!-->≥<!--> <!-->5 years was statistically significantly lower when compared to those non-MTX exposed patients (17 [IQR 15] versus 20 [IQR 7.7]; <em>P</em> <!-->=<!--> <!-->0.04) and compared to those treated for<!--> <!--><<!--> <!-->5 years (17 [IQR 15] versus 20 [IQR 7]; <em>P</em> <!-->=<!--> <!-->0.01). A negative correlation was identified between the total IIEF5 score and MTX time exposure (<em>r</em> <!-->=<!--> <!-->–0.20 CI [–0.38 to –0.04]; <em>P</em> <!-->=<!--> <!-->0.039). MTX exposure was still associated with a lower IIEF5 score when adjusted for age (β Estimate<!--> <!-->=<!--> <!-->–2.63; CI [–5.13 to –0.13]; <em>P</em> <!-->=<!--> <!-->0.039). Hormonal dosage was similar in both groups for all hormones evaluated.</p></div><div><h3>Conclusion</h3><p>MTX exposure was associated with a lower IIEF5 score in male patients adjusted for age. The preliminary results need to be confirmed in larger prospective studies.</p></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sexual dysfunction in male patients treated with methorexate for arthritis: Analysis of the IIEF5 questionnaire and hormonal status\",\"authors\":\"Francesco Natalucci , Sandra Bisseron , Tatiana Sokolova , Aleksandra Avramovska , Dominique Maiter , Patrick Durez\",\"doi\":\"10.1016/j.jbspin.2024.105716\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>The aim of this study is to evaluate the impact of methotrexate (MTX) on erectile function in male patients through the International Index of Erectile Function (IIEF5) questionnaire and hormonal dosage.</p></div><div><h3>Methods</h3><p>Male patients affected by inflammatory arthritis (rheumatoid arthritis [RA] or psoriatic arthritis [PsA]) with good disease control and treated with chronic MTX were enrolled. Age-matched patients affected by chronic arthritis not treated with MTX were enrolled as controls. Each patient had a complete sexual hormone evaluation. IIEF5 questionnaire was administered to each patient.</p></div><div><h3>Results</h3><p>One hundred and nine patients were included, 77 in the MTX group and 32 as controls. The median weekly MTX dose was 10<!--> <!-->mg (IQR 7.5) with a median MTX duration therapy of 8 years (IQR 17). The total IIEF5 score was lower in patients MTX exposed compared to the control group without a significant result. The total IIEF5 score of patients treated with MTX<!--> <!-->≥<!--> <!-->5 years was statistically significantly lower when compared to those non-MTX exposed patients (17 [IQR 15] versus 20 [IQR 7.7]; <em>P</em> <!-->=<!--> <!-->0.04) and compared to those treated for<!--> <!--><<!--> <!-->5 years (17 [IQR 15] versus 20 [IQR 7]; <em>P</em> <!-->=<!--> <!-->0.01). A negative correlation was identified between the total IIEF5 score and MTX time exposure (<em>r</em> <!-->=<!--> <!-->–0.20 CI [–0.38 to –0.04]; <em>P</em> <!-->=<!--> <!-->0.039). MTX exposure was still associated with a lower IIEF5 score when adjusted for age (β Estimate<!--> <!-->=<!--> <!-->–2.63; CI [–5.13 to –0.13]; <em>P</em> <!-->=<!--> <!-->0.039). Hormonal dosage was similar in both groups for all hormones evaluated.</p></div><div><h3>Conclusion</h3><p>MTX exposure was associated with a lower IIEF5 score in male patients adjusted for age. The preliminary results need to be confirmed in larger prospective studies.</p></div>\",\"PeriodicalId\":54902,\"journal\":{\"name\":\"Joint Bone Spine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Joint Bone Spine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1297319X24000277\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Joint Bone Spine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1297319X24000277","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Sexual dysfunction in male patients treated with methorexate for arthritis: Analysis of the IIEF5 questionnaire and hormonal status
Objective
The aim of this study is to evaluate the impact of methotrexate (MTX) on erectile function in male patients through the International Index of Erectile Function (IIEF5) questionnaire and hormonal dosage.
Methods
Male patients affected by inflammatory arthritis (rheumatoid arthritis [RA] or psoriatic arthritis [PsA]) with good disease control and treated with chronic MTX were enrolled. Age-matched patients affected by chronic arthritis not treated with MTX were enrolled as controls. Each patient had a complete sexual hormone evaluation. IIEF5 questionnaire was administered to each patient.
Results
One hundred and nine patients were included, 77 in the MTX group and 32 as controls. The median weekly MTX dose was 10 mg (IQR 7.5) with a median MTX duration therapy of 8 years (IQR 17). The total IIEF5 score was lower in patients MTX exposed compared to the control group without a significant result. The total IIEF5 score of patients treated with MTX ≥ 5 years was statistically significantly lower when compared to those non-MTX exposed patients (17 [IQR 15] versus 20 [IQR 7.7]; P = 0.04) and compared to those treated for < 5 years (17 [IQR 15] versus 20 [IQR 7]; P = 0.01). A negative correlation was identified between the total IIEF5 score and MTX time exposure (r = –0.20 CI [–0.38 to –0.04]; P = 0.039). MTX exposure was still associated with a lower IIEF5 score when adjusted for age (β Estimate = –2.63; CI [–5.13 to –0.13]; P = 0.039). Hormonal dosage was similar in both groups for all hormones evaluated.
Conclusion
MTX exposure was associated with a lower IIEF5 score in male patients adjusted for age. The preliminary results need to be confirmed in larger prospective studies.
期刊介绍:
Bimonthly e-only international journal, Joint Bone Spine publishes in English original research articles and all the latest advances that deal with disorders affecting the joints, bones, and spine and, more generally, the entire field of rheumatology.
All submitted manuscripts to the journal are subjected to rigorous peer review by international experts: under no circumstances does the journal guarantee publication before the editorial board makes its final decision. (Surgical techniques and work focusing specifically on orthopedic surgery are not within the scope of the journal.)Joint Bone Spine is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.